Loading...
•
Jun 30, 2021
Amneal Q2 2021 Earnings Report
Amneal's Q2 2021 financial results were announced, featuring net revenue of $535 million and GAAP net income of $15 million.
Key Takeaways
Amneal Pharmaceuticals reported a strong second quarter in 2021, with net revenue reaching $535 million, a 15% increase compared to the second quarter of 2020. The company's GAAP net income was $15 million, a significant improvement from the net loss of $12 million in the same period last year. Adjusted EBITDA was $151 million, up 50% year-over-year, and adjusted diluted EPS was $0.25, a 92% increase.
Net revenue for Q2 2021 was $535 million, a 15% increase year-over-year.
GAAP net income for Q2 2021 was $15 million, compared to a net loss of $12 million in Q2 2020.
Adjusted EBITDA for Q2 2021 was $151 million, a 50% increase year-over-year.
Adjusted diluted EPS for Q2 2021 was $0.25, a 92% increase year-over-year.
Revenue by Segment
Forward Guidance
Amneal is maintaining its previously provided full year 2021 financial guidance.
Positive Outlook
- Net revenue: $2.1 billion - $2.2 billion
- Adjusted EBITDA: $500 million - $540 million
- Adjusted diluted EPS: $0.70 - $0.85
- Operating cash flow: $220 million - $250 million
- Capital expenditures: $60 million - $70 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...